We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other ...

HC Wainwright reaffirmed their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $110 ...

Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the appointment of Maninder ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target of $20.00. Discover outperforming stocks and invest ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Morgan Stanley upgrades Vir Biotechnology to Overweight with a $20 price target. Get Pro-Level Earnings Insights Before the Market Moves Data show encouraging preliminary safety and efficacy ...

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. Vir Biotechnology's Phase 1 trials reveal ...

In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller ...